CUTANEOUS SQUAMOUS CELL CARCINOMA
Clinical trials for CUTANEOUS SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CUTANEOUS SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo for advanced cancers halted early
Disease control TerminatedThis study tested a new drug (SOT101) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combination could shrink tumors. The study was stopped early, and participants were expected to need ongoing…
Matched conditions: CUTANEOUS SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated May 17, 2026 03:17 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-phase study tested a new drug called INCB099318 in 105 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are limit…
Matched conditions: CUTANEOUS SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 17, 2026 03:16 UTC
-
Promising skin cancer combo study halted early
Disease control TerminatedThis study tested whether adding an experimental drug (NT-I7) to an existing immunotherapy (atezolizumab) could help people with advanced skin cancers like melanoma, Merkel cell carcinoma, and squamous cell carcinoma. The trial enrolled 31 adults whose cancers had not responded t…
Matched conditions: CUTANEOUS SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
Promising combo cancer therapy trial halted early
Disease control TerminatedThis study tested whether injecting a drug called vidutolimod directly into tumors, combined with an intravenous immunotherapy (cemiplimab), could shrink or control advanced cancers like Merkel cell carcinoma, skin cancer, breast cancer, and lung cancer. The trial enrolled 77 adu…
Matched conditions: CUTANEOUS SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:50 UTC